HUE045699T2 - Genotípus- és fenotípus-alapú gyógyászati készítmények - Google Patents

Genotípus- és fenotípus-alapú gyógyászati készítmények

Info

Publication number
HUE045699T2
HUE045699T2 HUE13725157A HUE13725157A HUE045699T2 HU E045699 T2 HUE045699 T2 HU E045699T2 HU E13725157 A HUE13725157 A HU E13725157A HU E13725157 A HUE13725157 A HU E13725157A HU E045699 T2 HUE045699 T2 HU E045699T2
Authority
HU
Hungary
Prior art keywords
genotype
phenotype
medicinal formulations
based medicinal
formulations
Prior art date
Application number
HUE13725157A
Other languages
English (en)
Inventor
Stefan Willmann
Thomas Eissing
Kristin Dickschen
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of HUE045699T2 publication Critical patent/HUE045699T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE13725157A 2012-06-01 2013-05-27 Genotípus- és fenotípus-alapú gyógyászati készítmények HUE045699T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12170401.9A EP2668945A1 (de) 2012-06-01 2012-06-01 Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen

Publications (1)

Publication Number Publication Date
HUE045699T2 true HUE045699T2 (hu) 2020-01-28

Family

ID=48520964

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13725157A HUE045699T2 (hu) 2012-06-01 2013-05-27 Genotípus- és fenotípus-alapú gyógyászati készítmények

Country Status (23)

Country Link
US (3) US10285958B2 (hu)
EP (2) EP2668945A1 (hu)
JP (2) JP6096289B2 (hu)
KR (1) KR102129043B1 (hu)
CN (2) CN104507464A (hu)
AR (2) AR091234A1 (hu)
AU (1) AU2013269793B2 (hu)
BR (1) BR112014030059B1 (hu)
CA (1) CA2875189C (hu)
DK (1) DK2854789T3 (hu)
ES (1) ES2744306T3 (hu)
HK (1) HK1207296A1 (hu)
HU (1) HUE045699T2 (hu)
IL (1) IL235988B (hu)
MX (1) MX370304B (hu)
NZ (1) NZ702849A (hu)
PL (1) PL2854789T3 (hu)
PT (1) PT2854789T (hu)
RU (1) RU2683260C2 (hu)
SA (1) SA113340607B1 (hu)
SG (2) SG10201610072UA (hu)
TW (1) TWI644666B (hu)
WO (1) WO2013178565A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668945A1 (de) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US11965206B2 (en) 2018-12-21 2024-04-23 John Stoddard Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1317546C (en) 1985-07-01 1993-05-11 Werner Meier Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d
US6048857A (en) 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5580728A (en) 1994-06-17 1996-12-03 Perlin; Mark W. Method and system for genotyping
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6760708B1 (en) 1999-08-19 2004-07-06 Dell Products L.P. Method and system for migrating stored data to a build-to-order computing system
WO2001053460A1 (en) 2000-01-21 2001-07-26 Variagenics, Inc. Identification of genetic components of drug response
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
CN101856348A (zh) * 2003-08-29 2010-10-13 斯隆-凯特林癌症研究所 联合治疗癌症的方法
US7504214B2 (en) * 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
DE10345836A1 (de) 2003-10-02 2005-04-21 Bayer Technology Services Gmbh Verfahren zur Simulation der Wechselwirkung von chemischen Substanzen mit lebenden Organismen
JP4732683B2 (ja) 2003-12-29 2011-07-27 ユニバーサル・バイオ・リサーチ株式会社 標的物質の検出方法
WO2005092314A1 (en) 2004-03-18 2005-10-06 Istituto Nazionale Per Lo Studio E La Cura Del Tum 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer
WO2005094363A2 (en) 2004-03-30 2005-10-13 New York University System, method and software arrangement for bi-allele haplotype phasing
DE102004025534A1 (de) 2004-05-25 2005-12-15 Bayer Technology Services Gmbh Verfahren zur (zweistufigen) Dosis- und Dosierungsfindung
US8024128B2 (en) 2004-09-07 2011-09-20 Gene Security Network, Inc. System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data
US8147615B2 (en) 2004-11-05 2012-04-03 Infineon Technologies Ag Method of fabricating semiconductor cleaners
US20070098797A1 (en) * 2005-06-02 2007-05-03 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine
US20070122824A1 (en) 2005-09-09 2007-05-31 Tucker Mark R Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime
EP1938231A1 (en) 2005-09-19 2008-07-02 BG Medicine, Inc. Correlation analysis of biological systems
RU2318508C2 (ru) * 2005-12-28 2008-03-10 Всеволод Иванович Киселев Фармацевтическая композиция для лечения и профилактики пролиферативных заболеваний молочной железы
FR2896896B1 (fr) 2006-02-02 2009-09-25 Commissariat Energie Atomique Procede de classification d'evenements ou d'etats en deux etapes
DE102006028232A1 (de) 2006-06-20 2007-12-27 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
CA2669913C (en) 2006-11-21 2012-09-18 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions
US8099298B2 (en) 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
CA2716456A1 (en) 2008-02-26 2009-09-03 Purdue Research Foundation Method for patient genotyping
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
KR101813721B1 (ko) 2008-06-30 2017-12-29 토카겐 인크. 5-플루오르시토신 제제 및 이의 용도
JP4517312B2 (ja) * 2008-07-08 2010-08-04 ソニー株式会社 メモリアクセス制御装置および撮像装置
WO2010022143A2 (en) * 2008-08-19 2010-02-25 Mayo Foundation For Medical Education And Research Assessing and treating breast cancer patients
WO2010036732A1 (en) 2008-09-25 2010-04-01 Zeltiq Aesthetics, Inc. Treatment planning systems and methods for body contouring applications
US7873482B2 (en) 2008-12-16 2011-01-18 Bruno Stefanon Diagnostic system for selecting nutrition and pharmacological products for animals
US20120088247A1 (en) 2009-02-23 2012-04-12 Indian University Research & Technology Corporatio Materials and methods for treating patients with taxoxifen
WO2011072244A1 (en) * 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
US9372198B2 (en) 2010-06-17 2016-06-21 Aradigm Corporation Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals
EP2613783B1 (en) * 2010-08-26 2019-06-12 IPCA Laboratories Limited Methods for the treatment or prophylaxis of thrombosis or embolism
MX344435B (es) * 2011-06-27 2016-12-14 Ipca Laboratories Ltd * Compuestos antitromboticos.
SG10201608234UA (en) 2012-04-02 2016-11-29 Berg Llc Interrogatory cell-based assays and uses thereof
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US9417221B2 (en) 2013-08-27 2016-08-16 International Business Machines Corporation Food steganography

Also Published As

Publication number Publication date
EP2854789B1 (de) 2019-06-26
US20150174082A1 (en) 2015-06-25
AU2013269793B2 (en) 2018-03-01
US10285958B2 (en) 2019-05-14
BR112014030059A2 (pt) 2017-07-25
PT2854789T (pt) 2019-09-18
RU2014154140A (ru) 2016-07-27
IL235988B (en) 2018-11-29
IL235988A0 (en) 2015-01-29
WO2013178565A1 (de) 2013-12-05
TW201400109A (zh) 2014-01-01
JP2015519350A (ja) 2015-07-09
EP2668945A1 (de) 2013-12-04
TWI644666B (zh) 2018-12-21
CN104507464A (zh) 2015-04-08
SG11201407791VA (en) 2015-01-29
HK1207296A1 (en) 2016-01-29
MX370304B (es) 2019-12-09
US20170326080A1 (en) 2017-11-16
US20170326081A1 (en) 2017-11-16
RU2683260C2 (ru) 2019-03-27
SG10201610072UA (en) 2017-01-27
MX2014014596A (es) 2015-03-03
NZ702849A (en) 2016-09-30
ES2744306T3 (es) 2020-02-24
AU2013269793A1 (en) 2015-01-22
AR091234A1 (es) 2015-01-21
PL2854789T3 (pl) 2019-12-31
KR102129043B1 (ko) 2020-07-01
BR112014030059B1 (pt) 2022-12-06
KR20150022894A (ko) 2015-03-04
AR118842A2 (es) 2021-11-03
EP2854789A1 (de) 2015-04-08
CA2875189C (en) 2020-09-22
SA113340607B1 (ar) 2018-05-09
DK2854789T3 (da) 2019-09-16
JP2017048234A (ja) 2017-03-09
JP6096289B2 (ja) 2017-03-15
CN110075097A (zh) 2019-08-02
CA2875189A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
IL252566A0 (en) Pharmacy preparations and methods
HK1209079A1 (en) Catalytic forms and formulations
EP2861234A4 (en) PROGESTERONE FORMULATIONS
HK1203812A1 (en) Novel pharmaceutical formulations
HK1210714A1 (en) Antibody formulations and uses thereof
ZA201501124B (en) Trans-clomiphene formulations and uses thereof
HK1203050A1 (en) Novel dosage and formulation
HUE038237T2 (hu) Gyógynövény alapú készítmények
PT2908835T (pt) Formulações estáveis
HK1203411A1 (en) Inulin and inulin acetate formulations
PT2854789T (pt) Formulações farmacêuticas baseadas no genótipo ou fenótipo
GB201208315D0 (en) Pharmaceutical methods and compositions
HK1209339A1 (en) Pharmaceutical formulations
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations
GB201206178D0 (en) Formulations
GB201113314D0 (en) Formulations and processes